Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

ABSTRACT:

Background

Glembatumumab vedotin is an antibody-auristatin conjugate that targets cells expressing the transmembrane glycoprotein NMB (GPNMB, also known as osteoactivin). It has entered clinical evaluation for adult cancers that express GPNMB, including melanoma and breast cancer.

Procedures

Glembatumumab vedotin was administered intravenously at a dose of 2.5 mg/kg using a weekly × 3 schedule, and its antitumor activity was evaluated against selected Pediatric Preclinical Testing Program (PPTP) solid tumor xenografts using standard PPTP response metrics.

Results

Among PPTP xenografts, GPNMB was primarily expressed on the osteosarcoma xenografts, all of which expressed GPNMB at the RNA level, although at varying levels. Protein expression assessed by immunohistochemis

SUBMITTER: Kolb EA 

PROVIDER: S-EPMC4280502 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature